Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients

BACKGROUND: Sirukumab, a high-affinity human monoclonal antibody that selectively binds to interleukin-6, has demonstrated efficacy in the treatment of rheumatoid arthritis (RA) in global phase 1 and phase 2 studies. The present study evaluated the safety and efficacy of sirukumab, as monotherapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeuchi, Tsutomu, Yamanaka, Hisashi, Harigai, Masayoshi, Tamamura, Ryo, Kato, Yuichi, Ukyo, Yoshifumi, Nakano, Toshikazu, Hsu, Benjamin, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842593/
https://www.ncbi.nlm.nih.gov/pubmed/29514712
http://dx.doi.org/10.1186/s13075-018-1536-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842593/
https://www.ncbi.nlm.nih.gov/pubmed/29514712
http://dx.doi.org/10.1186/s13075-018-1536-9

Ejemplares similares